While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. Keeping that in mind, here are three profitable companies to steer clear of and a few better alternatives.
Somnigroup (SGI)
Trailing 12-Month GAAP Operating Margin: 10.1%
Established through the merger of Tempur-Pedic and Sealy in 2012, Somnigroup (NYSE:SGI) is a bedding manufacturer known for its innovative memory foam mattresses and sleep products
Why Do We Think SGI Will Underperform?
- 15.3% annual revenue growth over the last five years was slower than its consumer discretionary peers
- Free cash flow margin is expected to remain in place over the coming year
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Somnigroup is trading at $80.02 per share, or 25x forward P/E. Read our free research report to see why you should think twice about including SGI in your portfolio.
Integra LifeSciences (IART)
Trailing 12-Month GAAP Operating Margin: 9.7%
Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.
Why Are We Out on IART?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- 19 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
- 6× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
Integra LifeSciences’s stock price of $9.61 implies a valuation ratio of 4.2x forward P/E. Dive into our free research report to see why there are better opportunities than IART.
Illumina (ILMN)
Trailing 12-Month GAAP Operating Margin: 18.6%
Pioneering the ability to read the human genome at unprecedented speed and affordability, Illumina (NASDAQ:ILMN) develops and sells advanced DNA sequencing and microarray technologies that allow researchers and clinicians to analyze genetic variations and functions.
Why Does ILMN Worry Us?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Annual earnings per share growth of 1.5% underperformed its revenue over the last five years, partly because it diluted shareholders
- Low returns on capital reflect management’s struggle to allocate funds effectively
At $124.81 per share, Illumina trades at 25x forward P/E. Check out our free in-depth research report to learn more about why ILMN doesn’t pass our bar.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.